Health 28 sources · over 4 days 41 articles

Moderna Cancer Vaccine Data Leak Triggers Selloff Despite Positive Trial Results

Moderna and Merck's melanoma vaccine delivered positive late-stage results, but a data leak and falling shares have exposed a sharp divide between investors and cancer specialists.

Read the full story → · Latest coverage 26 Oct 2026, 9:52 am UTC

Chapters · 2

  1. 1Moderna shares plunge after cancer vaccine data leak unsettles investors
  2. 2Moderna Cancer Vaccine Data Leak Triggers Selloff Despite Positive Trial Results

Key moments · 9

Unverified vaccine report circulates on social platform X

ABC ↗

Moderna shares plunge about 25%, reversing vaccine optimism

Forbes ↗

Full trial data released later Thursday appear positive

CNBC ↗

Coverage gives conflicting figures for the reported benefit

Financial Times ↗

Reports detail 42% reduction in melanoma recurrence or death

CNN Brasil ↗

New coverage reports reduced risk of melanoma spreading

Times now ↗

Melanoma specialists call vaccine results clinically meaningful

CNBC ↗

Reports say personalised vaccine could win US approval in 2027

New Scientist ↗

After trial presentation, focus shifts to expanding treatment impact

STAT News ↗

Coverage by day

newest first

1 article

  1. Vaccino anti cancro a mRNA abbatte rischio di recidiva o morte per melanoma, Ascierto: “Nuova era per oncologia”
    Fanpage

2 articles

  1. STAT+: After a cancer vaccine’s first success, the race is on to expand the impact
    STAT News
  2. The world’s first-ever cancer vaccine has slashed the risk of tumour recurrence by a staggering 42 per cent in clinical…
    sozootoday

3 articles

  1. Melanoma, primo vaccino 'su misura' riduce il rischio di recidiva del 42%
    RSS di - ANSA.it
  2. Personalised cancer vaccine cuts skin cancer recurrence risk by 42%: What this means for patients
    Indian Express
  3. A Cancer Vaccine Made Just For You? Personalised mRNA Jab Cuts Melanoma Recurrence Risk By 49% In Major Trial
    Top World News- News18.com

18 articles

  1. Oncologists Cheer Melanoma Data
    Bloomberg
  2. A personalized cancer vaccine could be available as soon as 2027. Here’s what we know
    Fast Company
  3. The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
    MarketWatch
  4. Personalized mRNA vaccine for melanoma cut risk of cancer’s return in late-stage trial
    NBC News
  5. Moderna e Merck divulgam dados de vacina contra câncer após vazamento nas redes sociais
    Notícias ao Minuto

16 articles

  1. A Personalized Cancer Vaccine Lowers Melanoma Recurrence by 42%
    TIME.com
  2. ‘Landmark moment’: Sydney scientist’s world-first cancer breakthrough revealed
    Sydney Morning Herald
  3. Here’s what Moderna’s latest mRNA cancer vaccine data actually show
    Scientific American Content: Global Science
  4. A novel mRNA cancer vaccine helps reduce the chances of melanoma patients' tumors returning
    Top Stories
  5. Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
    Ars Technica Tech